OptiNose, Inc. provided revenue guidance for full year of 2023. The Company expects XHANCE net revenues for the full year of 2023 to be between $62.0 million to $68.0 million. In addition, the Company expects the full year 2023 XHANCE average net revenue per prescription to be approximately $200.